First Patient Dosed in EXIST Phase 2a Study for Parkinson's Disease
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has marked a significant milestone in the treatment of Parkinson's disease by dosing the first patient in the EXIST Phase 2a clinical trial. This study aims to evaluate the safety and tolerability of exidavnemab, a groundbreaking monoclonal antibody targeting aggregated forms of the ?-synuclein protein, which is associated with the progression of various neurological disorders, including Parkinson's disease.
Details of the EXIST Phase 2a Study
The EXIST (EXIdavnemab Synucleinopathy Trial) represents a randomized, double-blind, placebo-controlled study focused on patients with Parkinson's disease. The objective is to assess not just the safety profile of exidavnemab but also its tolerability in participants.
Study Structure and Cohorts
In this study, the recruitment of at least 24 patients has commenced, who will be divided into two distinct cohorts. Cohort 1 will receive either a lower dose of exidavnemab or a placebo, while Cohort 2 will be assigned a higher dose or a placebo. Each participant will contribute valuable data, as the study will extend beyond primary endpoints to include a comprehensive analysis of various biomarkers found in plasma, cerebrospinal fluid (CSF), and through digital measurements. This broad approach not only enhances the research's depth but also ensures a holistic view of the treatment's effects.
Insights from BioArctic's CEO
Gunilla Osswald, the CEO of BioArctic, expressed enthusiasm about this development: "We are extremely excited that we have reached this important milestone — dosing the first patient in the EXIST Phase 2a study with exidavnemab. This accomplishment illustrates BioArctic's commitment to advancing our research and improving the lives of patients suffering from various neurological disorders." This quote underscores the company's dedication to innovation and patient-centric development.
Previous Findings on Exidavnemab
Prior to this phase of development, two separate Phase 1 studies were conducted collaboratively with AbbVie. The findings of these studies, published in The Journal of Clinical Pharmacology, demonstrated that exidavnemab is generally well-tolerated, exhibiting an impressive half-life of approximately 30 days. Coupled with its high affinity and selectivity for targeting aggregated forms of ?-synuclein, these properties are crucial for maintaining effective binding within the brain and establish a strong foundation for the ongoing Phase 2a study.
About Exidavnemab
Exidavnemab represents a novel therapeutic approach, aiming to selectively bind and eliminate pathological aggregated forms of ?-synuclein, such as oligomers, protofibrils, and fibrillary aggregates. The overarching goal of this treatment is to halt or significantly slow the progression of neurodegenerative diseases like Parkinson's and other synucleinopathies, offering patients a much-needed breakthrough in their treatment options.
About BioArctic AB
Founded on innovative research principles, BioArctic AB (publ) is a Swedish biopharmaceutical company dedicated to developing forward-thinking treatments that can potentially delay or completely halt the progression of neurodegenerative diseases. One of the company's notable achievements includes the creation of Leqembi (lecanemab), recognized as the world's first drug to demonstrate efficacy in slowing the progression of early Alzheimer's disease and mitigating cognitive impairment.
In collaboration with its partner Eisai, BioArctic is actively involved in regulatory interactions and the global commercialization of Leqembi. Beyond this, BioArctic is expanding its research portfolio, actively developing antibodies targeting diseases such as Parkinson's disease and ALS. The company is also exploring several other projects aimed at tackling Alzheimer's disease. Leveraging its proprietary BrainTransporter™ technology, BioArctic aims to enhance the efficacy of its treatments by enabling antibodies to effectively cross the blood-brain barrier, a critical factor in the development of new therapeutic options.
Frequently Asked Questions
What is the EXIST Phase 2a study?
The EXIST Phase 2a study is a clinical trial evaluating the safety and tolerability of exidavnemab in patients with Parkinson's disease.
Who is BioArctic AB?
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases like Parkinson's and Alzheimer's.
What is the role of exidavnemab?
Exidavnemab is designed to selectively target and eliminate aggregated forms of ?-synuclein implicated in the progression of Parkinson's disease.
Where is the EXIST study being conducted?
The EXIST Phase 2a study is being conducted across various locations in Europe.
What previous studies were conducted on exidavnemab?
Two Phase 1 studies conducted in collaboration with AbbVie indicated that exidavnemab is well-tolerated with a favorable pharmacokinetic profile.
